Research Analysts Issue Forecasts for Alkermes Q3 Earnings

Alkermes plc (NASDAQ:ALKS) – Equities researchers at HC Wainwright cut their Q3 2026 EPS estimates for Alkermes in a report released on Wednesday, July 29th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings of ($0.09) per share for the quarter, down from their prior estimate of $0.03. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Alkermes’ current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for Alkermes’ Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at ($0.43) EPS, FY2028 earnings at ($0.29) EPS, FY2029 earnings at $0.55 EPS and FY2030 earnings at $1.36 EPS.

ALKS has been the subject of several other research reports. Royal Bank Of Canada lifted their price objective on Alkermes from $45.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, June 9th. Weiss Ratings lowered Alkermes from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Zacks Research raised Alkermes from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. UBS Group lifted their price target on Alkermes from $42.00 to $48.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Finally, Wells Fargo & Company upped their price target on shares of Alkermes from $44.00 to $65.00 and gave the stock an “overweight” rating in a research report on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $54.56.

Alkermes Stock Up 1.1%

NASDAQ ALKS opened at $49.53 on Monday. The stock’s 50 day simple moving average is $48.49 and its 200 day simple moving average is $38.38. Alkermes has a one year low of $25.17 and a one year high of $55.67. The firm has a market cap of $8.31 billion, a PE ratio of 130.35 and a beta of 0.34. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.30 and a quick ratio of 1.85.

Institutional Trading of Alkermes

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Baker BROS. Advisors LP lifted its position in Alkermes by 23.7% during the 4th quarter. Baker BROS. Advisors LP now owns 10,012,267 shares of the company’s stock valued at $280,143,000 after purchasing an additional 1,920,916 shares during the period. State Street Corp boosted its stake in shares of Alkermes by 10.9% in the 4th quarter. State Street Corp now owns 9,472,858 shares of the company’s stock valued at $265,051,000 after purchasing an additional 932,507 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Alkermes by 6.0% during the 4th quarter. Renaissance Technologies LLC now owns 6,668,028 shares of the company’s stock worth $186,571,000 after buying an additional 375,500 shares during the period. JPMorgan Chase & Co. grew its position in shares of Alkermes by 32.0% during the 4th quarter. JPMorgan Chase & Co. now owns 5,184,547 shares of the company’s stock worth $145,064,000 after buying an additional 1,256,377 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in shares of Alkermes by 2.5% during the first quarter. Dimensional Fund Advisors LP now owns 4,522,378 shares of the company’s stock worth $159,850,000 after buying an additional 109,595 shares during the last quarter. 95.21% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Alkermes

In other news, EVP David Joseph Gaffin sold 2,034 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $48.58, for a total transaction of $98,811.72. Following the completion of the sale, the executive vice president owned 225,456 shares in the company, valued at $10,952,652.48. The trade was a 0.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Craig C. Hopkinson sold 9,000 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $51.51, for a total value of $463,590.00. Following the transaction, the executive vice president directly owned 73,389 shares in the company, valued at $3,780,267.39. This trade represents a 10.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 79,574 shares of company stock valued at $3,901,478 over the last 90 days. 4.59% of the stock is currently owned by corporate insiders.

Key Stories Impacting Alkermes

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Analysts have assigned Alkermes a consensus rating of “Moderate Buy,” indicating that Wall Street’s overall stance remains favorable toward the company and its outlook. Alkermes Receives Consensus Recommendation of Moderate Buy
• Neutral Sentiment: HC Wainwright published an estimate for Alkermes’ third-quarter earnings. The report could influence trading as investors assess whether upcoming results can support the company’s premium valuation, although the specific estimate was not provided. HC Wainwright Estimates Alkermes’ Q3 Earnings
• Negative Sentiment: Director Nancy Lynn Md Snyderman sold 44,472 ALKS shares for approximately $2.24 million, reducing her direct ownership by about 74%. The sizable sale may raise concern about insider confidence, although the filing does not establish that the transaction reflects a negative view of the business. SEC insider transaction filing
• Negative Sentiment: EVP Craig C. Hopkinson sold 9,000 shares valued at roughly $437,000, cutting his direct holdings by 11.48%. The sale was made under a pre-arranged Rule 10b5-1 trading plan, which reduces its significance as a discretionary bearish signal. SEC insider transaction filing
• Negative Sentiment: EVP David Joseph Gaffin sold 2,034 shares for approximately $99,000, reducing ownership by 0.89%. This transaction also occurred under a pre-arranged Rule 10b5-1 plan and is relatively small compared with his remaining stake. SEC insider transaction filing

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.